Learn More
PURPOSE Gemcitabine requires transporter proteins to cross cell membranes. Low expression of human equilibrative nucleoside transporter-1 (hENT1) may result in gemcitabine resistance in pancreatic(More)
BACKGROUND The role of human equilibrative nucleoside transporter 1 (hENT1) as a predictive biomarker for gemcitabine efficacy in advanced pancreatic cancer remains unclear to date. PATIENTS AND(More)
TPS144 Background: Gemcitabine (Gem) is standard of care therapy for mPDAC, however many patients do not benefit. Gem requires a transporter protein, hENT1, to enter cells. Reduced tumor hENT1(More)
  • 1